— Jubbonti® and Wyost® are first denosumab biosimilars available in Canada, reflecting the Sandoz Purpose of pioneering access for patients
— Jubbonti® and Wyost® approved for all indications of respective reference medicines
— Sandoz Canada has a leading biosimilars portfolio, with many more in the pipeline
BOUCHERVILLE, Quebec, Aug. 12, 2024 – Sandoz Canada, a leader in generics and biosimilars, today announces the launch of two denosumab biosimilars: Jubbonti® and Wyost®.
Jubbonti® is available in 60 mg/mL solution in single-use prefilled syringe and is approved for treating osteoporosis and increasing bone mass. The product is expected to be listed on all provincial formularies in the near future.
Wyost® is available in 120 mg/1.7 mL solution for subcutaneous injection and is approved for the prevention of bone fractures in bone metastatic cancers and the treatment of bone giant cells tumors in adults. Both internal and external packaging include GS1 standard barcoding for easy identification.
Jubbonti® is approved for all indications of its reference medicine Prolia® while Wyost® is approved for all indications of its reference medicine Xgeva®.*
Michel Robidoux, President and General Manager, Sandoz Canada
“It is great news that Canadians will now have access to high-quality denosumab biosimilars. This launch reflects our deep commitment to our Purpose of pioneering access for patients, as Sandoz Canada is the first and only company to offer these biosimilars in the country.”
Patients and healthcare professionals will be able to benefit from the Sandoz Plus Patient Support Program services during their treatment with Wyost® or Jubbonti®.
Sandoz is dedicated to responding to the evolving needs of healthcare professionals and patients. Sandoz Canada’s biosimilars portfolio covers the areas of oncology, dermatology, gastroenterology, immunology and endocrinology.
* Xgeva® and Prolia® are registered trademarks of Amgen Inc.
Learn more
- February 20, 2024: Sandoz receives Health Canada approval for Jubbonti®, first and only denosumab biosimilar for treatment of osteoporosis
- March 4, 2024: Sandoz obtains Health Canada authorization to market Wyost®, first and only denosumab biosimilar for oncology indications
